Michael Reusch - Publications

POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery.

Journal: Trials

Published: April 17, 2025

Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study.

Journal: Transplantation direct

Published: June 10, 2024

Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.

Journal: EClinicalMedicine

Published: April 20, 2024

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease.

Journal: Journal of clinical medicine

Published: March 13, 2023

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.

Journal: Advances in therapy

Published: December 21, 2022

Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES).

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: February 11, 2022

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.

Journal: Advances in therapy

Published: June 24, 2021

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).

Journal: Advances in therapy

Published: June 24, 2021

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.

Journal: Kidney international reports

Published: April 02, 2021

Authors' Reply.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 02, 2021

Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.

Journal: Kidney international reports

Published: December 22, 2020

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: December 02, 2020